Pressure Biosciences (PBIO) AI Stock Analysis

• Market Cap: $4.10K
• Dividend Yield: N/A
• Average Volume (3M): 1.17K
• Price to Earnings (P/E): ―
• Beta (1Y): -3.61
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 40,967,083
• 10 Day Avg. Volume: 345
• 30 Day Avg. Volume: 1,173
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

Pressure Biosciences' score reflects significant financial instability with high leverage and negative cash flows. The absence of positive technical indicators and valuation metrics further weighs on the stock. The lack of guidance or sentiment from the earnings call adds uncertainty, limiting any positive outlook in the near term.

Pressure Biosciences Business Overview & Revenue Model

Company Description

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

How the Company Makes Money

Pressure BioSciences generates revenue primarily through the sale of its proprietary high-pressure instruments and consumable products. The company markets its Pressure Cycling Technology (PCT) systems to research institutions, biotechnology and pharmaceutical companies, and government entities. Revenue streams include direct sales of instruments, recurring sales of consumables required for ongoing use of the systems, and service contracts for maintenance and support of the equipment. Additionally, PBIO may engage in collaborative partnerships and licensing agreements that provide funding and the potential for milestone payments and royalties. The company's growth is supported by its focus on expanding applications for its technology across various sectors, thereby increasing its customer base and market penetration.

Pressure Biosciences Financial Statement Overview

Summary

Pressure Biosciences is facing significant financial challenges with negative net income, high debt levels, negative cash flows, and negative stockholders' equity, indicating financial instability and ongoing profitability issues.

Income Statement

Pressure Biosciences has shown some revenue growth from 2022 to 2023, but consistently negative net income and EBIT margins indicate ongoing profitability challenges. The net profit margin remains deeply negative, reflecting significant expenses relative to revenue.

Balance Sheet

The company has a negative stockholders' equity, indicating liabilities exceed assets, a concerning financial position. The high debt levels relative to equity suggest financial instability and potential difficulty in meeting long-term obligations.

Cash Flow

Operating cash flow is negative and free cash flow has not shown improvement, indicating cash generation issues. The company relies heavily on financing activities to support operations, which may not be sustainable long-term.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	1.98M	1.73M	2.00M	1.22M	1.81M
Gross Profit	799.56K	-284.66K	1.06M	637.74K	612.93K
EBITDA	-9.39M	-5.40M	-5.53M	-7.46M	-6.41M
Net Income	-29.31M	-16.82M	-34.60M	-24.35M	-11.66M
Balance Sheet
Total Assets	1.05M	2.01M	2.83M	2.30M	1.82M
Cash, Cash Equivalents and Short-Term Investments	81.28K	3.87K	132.31K	18.54K	29.63K
Total Debt	22.89M	20.53M	14.64M	9.60M	7.96M
Total Liabilities	33.80M	34.70M	25.04M	19.22M	13.87M
Stockholders Equity	-32.75M	-32.69M	-22.21M	-16.92M	-12.06M
Cash Flow
Free Cash Flow	-3.19M	-4.50M	-4.99M	-4.88M	-6.35M
Operating Cash Flow	-3.19M	-4.48M	-4.87M	-4.88M	-6.33M
Investing Cash Flow	-7.50K	-20.75K	-122.94K	-796.66K	-23.38K
Financing Cash Flow	3.27M	4.37M	5.11M	5.67M	6.28M

Pressure Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	78 Outperform	$1.04B	32.55	16.62%	―	6.85%	-67.67%
TMO	77 Outperform	$173.97B	26.67	13.44%	0.36%	2.05%	7.03%
TECH	75 Outperform	$7.90B	109.61	3.68%	0.63%	5.23%	-56.69%
BIO	72 Outperform	$7.15B	22.52	4.59%	―	-0.33%	―
Sector *	51 Neutral	$7.35B	-0.20	-44.53%	2.35%	30.18%	-1.17%
QDEL	50 Neutral	$1.62B	―	-14.80%	―	-3.00%	76.48%
PBIO	32 Underperform	$4.10K	―	89.50%	―	―	―